Lukas Biomedical Inc. (TPEX:6814)

Market Cap	601.60M -45.6%
Revenue (ttm)	170.01M -5.7%
Net Income	-92.05M
EPS	-2.20
Shares Out	32.87M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,103
Open	19.20
Previous Close	18.30
Day's Range	18.30 - 19.20
52-Week Range	17.30 - 32.50
Beta	0.09
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 13, 2026

About Lukas Biomedical

Lukas Biomedical Inc. engages in the wholesale and retail of cosmetics in Taiwan. The company operates through E-Commerce Department, Medical Management Business, Cell Products Department, and Pharmaceutical Market Development Department segments. It also researches and develops immune cell medical technology for regenerative medicine and adjuvant treatment; engages in clinical trials; distributes immune cell therapy culture technology; and leases building equipment. In addition, the company involved in the new immune cell research and developm...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2002
• Employees: 87
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6814

Financial Performance

In 2025, Lukas Biomedical's revenue was 179.49 million, a decrease of -5.44% compared to the previous year's 189.83 million. Losses were -85.63 million, -9.27% less than in 2024.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Sep 15, 2026

Data Sources Report a data error